Press Releases

Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

July 21, 2016

DURHAM, N.C. – Novan, Inc. today announced that the first patient has been dosed in the Company’s Phase 2 clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”).

Full Story

Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206

May 10, 2016

DURHAM, N.C. – Novan, Inc. today announced that Kimberly McHale, Ph.D., Novan Senior Scientist, Research & Nonclinical Development, will present data demonstrating a novel mechanism of action for the Company’s anti-viral product candidate, SB206, Saturday, May 14, at the 75th Annual Meeting of the Society for Investigative Dermatology in Scottsdale, Ariz.

Full Story

Novan's Phase 2b Results with SB204 to be Presented at AAD

March 1, 2016

DURHAM, N.C. – Novan, Inc. today announced that data from a Phase 2 clinical trial to evaluate the efficacy and safety of the Company’s topical nitric oxide product candidate SB204 Gel for the treatment of acne vulgaris will be presented at the 74th Annual Meeting of the American Academy of Dermatology (“AAD”) in Washington, D.C.

Full Story

Novan Announces First Patient Dosed in Phase 3 Program for SB204

February 23, 2016

DURHAM, N.C. – Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris.

Full Story

Close
Close